At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 139 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating Placebo and RG7774 for Diabetic Retinopathy. Completed, enrolled 139 participants across 68 sites in 7 countries.
Detailed Summary
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and good vision.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesAustralia, Poland, Puerto Rico, Slovakia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJun 2020
Primary CompletionJul 2023
TodayJul 2026
First PostedFeb 11, 2020
Enrollment StartJun 5, 2020
Primary CompletionJul 19, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.4 years ago
Interventions
Placebodrug
Participants will receive oral placebo matched to RG7774
RG7774drug
Participants will receive oral RG7774